William Blair Downgrades Sequenom (SQNM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Buy Sequenom (SQNM) Aggressively, Issues 'Not End of World' - Wedbush
July 25, 2013 9:43 AM EDTWedbush today maintained an Outperform rating on Sequenom (NASDAQ: SQNM) with a price target of $5.00. Shares tumbled as a result of disappointing earnings on Wednesday. Along with many other companies in the diagnostics industry, Sequenom experienced delays in receipt of payments as a result of... More
Ladenburg Thalmann Downgrades Sequenom (SQNM) to Neutral
July 25, 2013 8:24 AM EDTLadenburg Thalmann downgraded Sequenom (NASDAQ: SQNM) from Buy to Neutral.
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.69 yesterday, with a 52 week range of $2.65-$5.36.... More
Lazard Capital Downgrades Sequenom (SQNM) to Neutral
July 25, 2013 7:16 AM EDTLazard Capital downgraded Sequenom (NASDAQ: SQNM) from Buy to Neutral.
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.69 yesterday, with a 52 week range of $2.65-$5.36.... More
Sequenom, Inc. (SQNM) Posts Q2 Loss of 27c/Share; Issues MaterniT21 PLUS Update
July 24, 2013 4:08 PM EDTSequenom, Inc. (NASDAQ: SQNM) reported Q2 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $24.5 million versus the consensus estimate of $46.25 million.
Operations Update
The annualized run rate for the MaterniT21 PLUS test at the end of the second quarter surpassed 150,000 samples.
"We have managed through challenges associated with the tremendous growth in our business following the launch of MaterniT21 PLUS. Uncertainties associated with the newly introduced coding changes in the molecular... More
